HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (3- isopropyl- 5- (6- phenyl- 3- pyridyl)- 4H- 1,2,4- triazol- 4- yl)- 2,1,3- benzoxadiazole

inhibits glycine transporter 1; structure in first source

Also Known As:

ASP2535

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - 4-(3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl)-2,1,3-benzoxadiazole: 1
    - Oxazoles: 89
      - Oxadiazoles: 146
        4-(3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl)-2,1,3-benzoxadiazole: 1

Experts

1.	Aota, Masaki: 1 article (06/2012)
2.	Doihara, Hitoshi: 1 article (06/2012)
3.	Harada, Katsuya: 1 article (06/2012)
4.	Matsuoka, Nobuya: 1 article (06/2012)
5.	Morita, Masahiko: 1 article (06/2012)
6.	Nakato, Kazuhiro: 1 article (06/2012)
7.	Ni, Keni: 1 article (06/2012)
8.	Saita, Kyoko: 1 article (06/2012)
9.	Sato, Yuichiro: 1 article (06/2012)
10.	Takahashi, Shinji: 1 article (06/2012)

Related Diseases

1.	Cognitive Dysfunction 06/15/2012 - "These studies provide compelling evidence that ASP2535 is a novel and centrally-active GlyT1 inhibitor that can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease, suggesting that ASP2535 may satisfy currently unmet medical needs for the treatment of these diseases." 06/15/2012 - "We then evaluated the effect of ASP2535 on animal models of cognitive impairment in schizophrenia and Alzheimer's disease. " 06/15/2012 - "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease."
2.	Schizophrenia (Dementia Praecox) 06/15/2012 - "These studies provide compelling evidence that ASP2535 is a novel and centrally-active GlyT1 inhibitor that can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease, suggesting that ASP2535 may satisfy currently unmet medical needs for the treatment of these diseases." 06/15/2012 - "We then evaluated the effect of ASP2535 on animal models of cognitive impairment in schizophrenia and Alzheimer's disease. " 06/15/2012 - "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease."
3.	Alzheimer Disease (Alzheimer's Disease) 06/15/2012 - "These studies provide compelling evidence that ASP2535 is a novel and centrally-active GlyT1 inhibitor that can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease, suggesting that ASP2535 may satisfy currently unmet medical needs for the treatment of these diseases." 06/15/2012 - "We then evaluated the effect of ASP2535 on animal models of cognitive impairment in schizophrenia and Alzheimer's disease. " 06/15/2012 - "A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease."

Related Drugs and Biologics

1.	Glycine (Aminoacetic Acid)